BR112012014058A8 - Derivados de 3,4,4a,10b- tetraidro-1h- tiopirano[4,3-c]isoquinolina - Google Patents

Derivados de 3,4,4a,10b- tetraidro-1h- tiopirano[4,3-c]isoquinolina

Info

Publication number
BR112012014058A8
BR112012014058A8 BR112012014058A BR112012014058A BR112012014058A8 BR 112012014058 A8 BR112012014058 A8 BR 112012014058A8 BR 112012014058 A BR112012014058 A BR 112012014058A BR 112012014058 A BR112012014058 A BR 112012014058A BR 112012014058 A8 BR112012014058 A8 BR 112012014058A8
Authority
BR
Brazil
Prior art keywords
tetrahydro
thiopirane
isoquinoline derivatives
fixed combination
isoquinoline
Prior art date
Application number
BR112012014058A
Other languages
English (en)
Other versions
BR112012014058A2 (pt
Inventor
Flockerzi Dieter
Stengel Thomas
Mann Alexander
Ohmer Harold
Kautz Ulrich
Weinbrenner Steffen
Fischer Stefan
Zitt Christof
Hatzelmann Armin
Original Assignee
Takeda Gmbh
Nycomed Gmbh
Astrazeneca Ab
Nycomed Asset Man Gmbh
Nycomed Germany Holding Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh, Nycomed Gmbh, Astrazeneca Ab, Nycomed Asset Man Gmbh, Nycomed Germany Holding Gmbh filed Critical Takeda Gmbh
Publication of BR112012014058A2 publication Critical patent/BR112012014058A2/pt
Publication of BR112012014058A8 publication Critical patent/BR112012014058A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

DERIVADOS DE 3,4,4a,10b-TETRAIDRO-1H- TIO-PIRANO[4,3-c]ISOQUINOLINA, SEU USO, COMPOSIÇÃO FARMACÊUTICA, COMBINAÇÃO FIXA, E COMBINAÇÃO NÃO FIXA OU KIT DE PARTES. A presente invenção se refere aos compostos de fórmula 1, na qual A, R1, R2, R3 e R5 têm os significados conforme proporcionado no relatório descritivo, que são eficazes inibidores de fosfodiesterase tipo 4 e 5.
BR112012014058A 2009-12-18 2010-12-15 Derivados de 3,4,4a,10b- tetraidro-1h- tiopirano[4,3-c]isoquinolina BR112012014058A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09179982 2009-12-18
US31555210P 2010-03-19 2010-03-19
PCT/EP2010/069704 WO2011073231A1 (en) 2009-12-18 2010-12-15 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4, 3-c] ISOQUINOLINE DERIVATIVES

Publications (2)

Publication Number Publication Date
BR112012014058A2 BR112012014058A2 (pt) 2017-10-24
BR112012014058A8 true BR112012014058A8 (pt) 2018-02-06

Family

ID=41718903

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012014058A BR112012014058A8 (pt) 2009-12-18 2010-12-15 Derivados de 3,4,4a,10b- tetraidro-1h- tiopirano[4,3-c]isoquinolina

Country Status (29)

Country Link
US (1) US9018175B2 (pt)
EP (2) EP2813509B1 (pt)
JP (1) JP5645961B2 (pt)
KR (1) KR20120123313A (pt)
CN (1) CN102652136B (pt)
AR (1) AR079451A1 (pt)
AU (1) AU2010332955B8 (pt)
BR (1) BR112012014058A8 (pt)
CA (1) CA2784013A1 (pt)
CO (1) CO6551705A2 (pt)
DK (1) DK2513119T3 (pt)
EA (1) EA023212B1 (pt)
ES (2) ES2621291T3 (pt)
GE (1) GEP20146105B (pt)
HK (1) HK1174326A1 (pt)
HR (1) HRP20140893T1 (pt)
ME (1) ME01914B (pt)
MX (1) MX2012006696A (pt)
NZ (1) NZ601115A (pt)
PL (1) PL2513119T3 (pt)
PT (1) PT2513119E (pt)
RS (1) RS53544B1 (pt)
SG (2) SG196785A1 (pt)
SI (1) SI2513119T1 (pt)
SM (1) SMT201400185B (pt)
TW (1) TWI468411B (pt)
UA (1) UA107689C2 (pt)
WO (1) WO2011073231A1 (pt)
ZA (1) ZA201204135B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110300432A1 (en) 2010-06-07 2011-12-08 Snyder Shawn W Rechargeable, High-Density Electrochemical Device
RU2013142268A (ru) * 2011-02-17 2015-03-27 Сипла Лимитед Фармацевтическая композиция
EP2721036B1 (en) 2011-06-15 2015-07-22 Takeda GmbH Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c]isoquinoline compounds
WO2014016548A2 (en) * 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
WO2014090990A1 (en) * 2012-12-13 2014-06-19 Ludwig Aigner Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease
AU2014211755B2 (en) 2013-02-04 2017-07-06 Grunenthal Gmbh 4-amino substituted condensed pyrimidine compounds as PDE4 inhibitors
ES2638850T3 (es) 2013-02-19 2017-10-24 Pfizer Inc. Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
WO2016020786A1 (en) 2014-08-06 2016-02-11 Pfizer Inc. Imidazopyridazine compounds
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899494A (en) 1970-05-13 1975-08-12 Sandoz Ltd Substituted 6-phenyl benzo-naphthyridines
DE2047465A1 (de) 1970-09-26 1972-03-30 Farbwerke Hoechst AG, vorm Meister Lucius & Bruning, 6000 Frankfurt Neue Oxdiazole und Verfahren zu lh rer Herstellung
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH01213284A (ja) 1988-02-22 1989-08-28 Sankyo Co Ltd チエノピリミジン−２，４−ジオン誘導体
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
ATE111364T1 (de) 1989-05-31 1994-09-15 Fisons Plc Medikament und inhalationsvorrichtung dafür.
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
JPH05505824A (ja) 1990-03-23 1993-08-26 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 所定投与量エアロゾル製剤の製造のための可溶性弗素界面活性剤の使用
ATE114112T1 (de) 1990-10-18 1994-12-15 Minnesota Mining & Mfg Aerosolzubereitung, die beclometason 17,21- dipropionat enthält.
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
GB9213874D0 (en) 1992-06-30 1992-08-12 Fisons Plc Process to novel medicament form
GB9306703D0 (en) 1993-03-31 1993-05-26 Fisons Plc Inhalation device
IL111194A (en) 1993-10-08 1998-02-08 Fisons Plc Process for the production of drug patramulations
ES2195189T3 (es) 1996-11-11 2003-12-01 Altana Pharma Ag Benzonaftiridinas como agentes terapeuticos bronquiales.
ES2179490T3 (es) 1997-05-08 2003-01-16 Merck Sharp & Dohme Derivados de 1,2,4-triazolo(3,4-a)ftalazina sustituidos como ligandos de gaba alfa 5.
AU8106598A (en) 1997-06-03 1998-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine
CN1150890C (zh) 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
US6397838B1 (en) 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
US6454193B1 (en) 1999-04-23 2002-09-24 Battellepharma, Inc. High mass transfer electrosprayer
BR0009993A (pt) 1999-04-23 2002-01-08 Battelle Memorial Institute Pulverizador de aerossol eletrohidrodinâmico direcionalmente controlado, dispositivo para liberar gotìculas de aerossol eletricamente neutras, aparelho para liberar gotìculas de aerossol terapêuticas, processo para liberar gotìculas de aerossol, e, dispositivo para liberar aerossol
ATE312820T1 (de) 1999-10-28 2005-12-15 Trine Pharmaceuticals Inc Pumpeninhibitoren zur freisetzung von medikamenten
WO2001094350A1 (en) 2000-06-07 2001-12-13 Almirall Prodesfarma S.A. 6-phenylpyrrolopyrimidinedione derivatives
AU2001281965A1 (en) 2000-07-14 2002-01-30 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Novel 6-phenylphenanthridines
ES2260299T3 (es) 2000-10-09 2006-11-01 3M Innovative Properties Company Formulaciones medicinales en aerosol.
EP1425029A4 (en) 2001-08-10 2006-06-07 Palatin Technologies Inc PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES
US20030216407A1 (en) 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
GB0202254D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
MXPA06012279A (es) 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.
JP4960870B2 (ja) 2004-09-08 2012-06-27 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の３−チア−１０−アザ−フェナントレン誘導体
US7838521B2 (en) 2004-09-08 2010-11-23 Nycomed Gmbh 3-oxa-10-aza-phenanthrenes
EP1813603A1 (en) 2004-11-17 2007-08-01 Kissei Pharmaceutical Co., Ltd. Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both
JP2008532980A (ja) * 2005-03-09 2008-08-21 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング アミド置換された６−フェニルフェナントリジン
JP5309131B2 (ja) * 2007-04-23 2013-10-09 サノフイ Ｐ２ｙ１２アンタゴニストとしてのキノリン−カルボキサミド誘導体
EP2721036B1 (en) * 2011-06-15 2015-07-22 Takeda GmbH Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c]isoquinoline compounds

Also Published As

Publication number Publication date
ME01914B (me) 2015-05-20
EA023212B1 (ru) 2016-05-31
EP2813509A1 (en) 2014-12-17
US20120289474A1 (en) 2012-11-15
EP2513119A1 (en) 2012-10-24
WO2011073231A1 (en) 2011-06-23
AU2010332955B8 (en) 2015-05-21
TWI468411B (zh) 2015-01-11
SG196785A1 (en) 2014-02-13
CO6551705A2 (es) 2012-10-31
ES2621291T3 (es) 2017-07-03
ZA201204135B (en) 2013-03-27
PL2513119T3 (pl) 2014-11-28
JP2013514308A (ja) 2013-04-25
EP2513119B1 (en) 2014-06-25
AU2010332955B2 (en) 2015-01-22
KR20120123313A (ko) 2012-11-08
ES2505290T3 (es) 2014-10-09
RS53544B1 (en) 2015-02-27
EA201200891A1 (ru) 2013-01-30
NZ601115A (en) 2014-05-30
DK2513119T3 (da) 2014-10-06
AR079451A1 (es) 2012-01-25
CN102652136A (zh) 2012-08-29
SI2513119T1 (sl) 2014-10-30
TW201130851A (en) 2011-09-16
EP2813509B1 (en) 2017-02-01
MX2012006696A (es) 2012-07-17
HRP20140893T1 (hr) 2014-11-07
GEP20146105B (en) 2014-05-27
HK1174326A1 (en) 2013-06-07
UA107689C2 (en) 2015-02-10
SG180824A1 (en) 2012-07-30
JP5645961B2 (ja) 2014-12-24
BR112012014058A2 (pt) 2017-10-24
PT2513119E (pt) 2014-09-05
SMT201400185B (it) 2015-01-15
CN102652136B (zh) 2014-11-26
AU2010332955A1 (en) 2012-08-02
AU2010332955A8 (en) 2015-05-28
CA2784013A1 (en) 2011-06-23
US9018175B2 (en) 2015-04-28

Similar Documents

Publication Publication Date Title
BR112012014058A8 (pt) Derivados de 3,4,4a,10b- tetraidro-1h- tiopirano[4,3-c]isoquinolina
CY1115866T1 (el) Τριαζολοπυριμιδινες
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CO6741198A2 (es) Compuestos heterocíclicos nitrogenados sustituidos fusionados en posición 6,6 y usos de los mismos
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
UY32292A (es) Agonistas de s1p1 y métodos de preparación y uso
NI201200192A (es) Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica.
CR20140288A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
EA201071339A1 (ru) Фосфорсодержащие производные в качестве ингибиторов киназы
EA200970156A1 (ru) Пиридизиноновые производные
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
MA32369B1 (fr) Composes de benzene sulfonamide thiazole et oxazole
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
BRPI0814065B8 (pt) derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
ECSP099755A (es) Derivados de pirrolopiridina y su uso como inhibidores de bace
SV2011003855A (es) Heteroarilos sustituidos
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
BR112015012949A2 (pt) composto, composição farmaceutica, uso de um composto, dispositivo inalatório e kit
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
CR11157A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
BR112015012825A2 (pt) piridopirazinas substituídas como inibidores de syk

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TAKEDA GMBH (DE)

B25A Requested transfer of rights approved

Owner name: NYCOMED ASSET MANAGEMENT GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: NYCOMED GERMANY HOLDING GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: TAKEDA GMBH (DE)

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA AB (SE)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.